InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

Current share price for NEU : $20.200 0.23 (1.13%)+

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,561 Update - Notification of buy-back - NEU 9 Dec 2024 8:36AM $12.800 $20.200 risen by 57.81%
$2,561 Update - Notification of buy-back - NEU 6 Dec 2024 8:46AM $12.760 $20.200 risen by 58.31%
$2,561 Update - Notification of buy-back - NEU 5 Dec 2024 8:19AM $12.880 $20.200 risen by 56.83%
$2,561 Update - Notification of buy-back - NEU 4 Dec 2024 8:29AM $13.390 $20.200 risen by 50.86%
$2,561 Update - Notification of buy-back - NEU 3 Dec 2024 9:14AM $12.690 $20.200 risen by 59.18%
$2,561 Investor presentation, 15 November 2024 15 Nov 2024 10:19AM $16.990 $20.200 risen by 18.89%
$2,561 Notification of buy-back - NEU 14 Nov 2024 9:17AM $16.540 $20.200 risen by 22.13%
$2,561 Neuren announces A$50m on-market share buy-back program 14 Nov 2024 9:14AM $16.540 $20.200 risen by 22.13%
$2,561 Q3 2024 update 7 Nov 2024 10:19AM $13.270 $20.200 risen by 52.22%
$2,561 Pause in Trading 7 Nov 2024 10:02AM $13.270 $20.200 risen by 52.22%
$2,561 PRV sold for US$150m - Neuren to receive one third 6 Nov 2024 9:26AM $12.270 $20.200 risen by 64.63%
$2,561 Updated Share Trading Policy 1 Nov 2024 4:49PM $12.250 $20.200 risen by 64.90%
$2,561 Notification of cessation of securities - NEU 28 Oct 2024 4:30PM $12.610 $20.200 risen by 60.19%
$2,561 DAYBUE receives marketing authorization in Canada 17 Oct 2024 9:30AM $12.700 $20.200 risen by 59.06%
$2,561 NEU continues PMS P3 preparations after positive FDA meeting 7 Oct 2024 9:32AM $14.050 $20.200 risen by 43.77%
$2,561 H1 2024 financial results 27 Aug 2024 9:17AM $15.590 $20.200 risen by 29.57%
$2,561 Half Yearly Report and Accounts 27 Aug 2024 9:12AM $15.590 $20.200 risen by 29.57%
$2,561 Investor roadshow presentation, 19 August 2024 19 Aug 2024 9:33AM $15.570 $20.200 risen by 29.74%
$2,561 Change of Director's Interest Notice - J Basile 16 Aug 2024 4:49PM $15.570 $20.200 risen by 29.74%
$2,561 NNZ-2591 Angelman top-line results presentation 9 Aug 2024 10:43AM $15.780 $20.200 risen by 28.01%
$2,561 Phase 2 trial shows significant improvements in Angelman 9 Aug 2024 10:01AM $17.090 $20.200 risen by 18.20%
$2,561 Trading Halt 7 Aug 2024 10:08AM $17.090 $20.200 risen by 18.20%
$2,561 Pause in Trading 7 Aug 2024 9:55AM $17.090 $20.200 risen by 18.20%
$2,561 Q2 2024 update 7 Aug 2024 9:52AM $17.090 $20.200 risen by 18.20%
$2,561 Neuren to participate in upcoming US investor conferences 25 Jul 2024 9:10AM $20.720 $20.200 fallen by 2.51%

201 - 225 of 833 results

Page 9 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.